Evidence map›Paper›PMID 25972023›Full record

ArticleClinical infectious diseases : an official publication of the Infectious Diseases Society of America2015

Editorial Commentary: Pseudomonas aeruginosa Eradication: How Do We Measure Success?

Edith T Zemanick, Theresa A Laguna

Abstract readEditorialComment
PubMed Full text at PMC Publisher
In one paragraph

Article in Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Eradication ofTherapeutic advances in respiratory disease
    Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

2 authors.

Edith T ZemanickDepartment of Pediatrics, University of Colorado School of Medicine, Aurora.
Theresa A LagunaDepartment of Pediatrics, University of Minnesota School of Medicine, Minneapolis.

Funding

University of Minnesota Clinical and Translational Science Institute (UMN CTSI)UL1TR000114 · NCATS · UNIVERSITY OF MINNESOTA · PI BLAZAR, BRUCE R · 2012 to 2015
$35.0M
Airway Microbiome in Cystic Fibrosis Pulmonary ExacerbationsK23HL114883 · NHLBI · UNIVERSITY OF COLORADO DENVER · PI ZEMANICK, EDITH TOWLER · 2014 to 2017
$615k
NCATS NIH HHS UL1 TR000114NHLBI NIH HHS K23 HL114883
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Pseudomonas aeruginosaAnti-Bacterial AgentsCystic FibrosisFemaleHumansMalePseudomonas InfectionsAnti-Bacterial Agentsairway infectioncystic fibrosiseradicationoutcomesPseudomonas

Identifiers

PMID25972023
PMCPMC4530724

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.